- Quotes
- Dashboard
- Chart
- Historical Prices
- Options
- News & PR
- News
- Market Currents
- Press Releases
- Coverage
- Cramer
- Top Analysts
- Business Intelligence
- Transcripts
- Events
- Key Developments
- Earnings
- History & Projected
- Consensus
- Peer Earnings
- Filings
- SEC Filings
- Annual Report
- Financials
- Income Statement
- Balance Sheet
- Cash Flow
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
AVII Market Currents
more »
-
April 12 AVI BioPharma (AVII) says in an SEC filing its chief scientific officer, Peter Linsley, Ph.D., intends to resign from his position effective June 1. Shares -7.3% AH.
Comment![On the Move, Healthcare]
AVII in Focus
more »
AVII Related Articles
more »
AVII News
more »
-
at MarketWatch.com (Apr 1, 2011)
-
at MarketWatch.com (Apr 1, 2011)
-
at MarketWatch.com (Jun 14, 2010)
AVII Press Releases and Filings
more »
-
Marketwire (May 10, 2012)
-
Marketwire (May 3, 2012)
-
Marketwire (Apr 25, 2012)
-
Marketwire (Mar 27, 2012)
-
Marketwire (Mar 12, 2012)
AVII Latest Transcript
more »
AVII Cramer
more »
Currently, there are no Cramer articles on AVII.
AVII Instablog posts
more »
AVII vs. ETF Alternatives
Company Description
AVI BioPharma is a biopharmaceutical Company specializing in the discovery and development of novel, RNA-based drugs targeting a range of diseases (in this report, “we,” “our,” “us,” “AVI,” and “Company” refers to AVI BioPharma, Inc.).
As one of the emerging leaders in the fast growing field... More
